James B Froehlich
Overview
Explore the profile of James B Froehlich including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
123
Citations
2520
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
2.
Ardeshna N, Feldeisen T, Kong X, Haymart B, Kaatz S, Ali M, et al.
Vasc Med
. 2024 Aug;
29(5):543-552.
PMID: 39177515
Introduction: Direct oral anticoagulants (DOACs) have overtaken warfarin in the treatment of nonvalvular atrial fibrillation (AF) and venous thromboembolism (VTE). Limited data explore the safety of DOACs in obesity. Methods:...
3.
Herron G, DeCamillo D, Kong X, Haymart B, Kaatz S, Ellsworth S, et al.
Thromb Haemost
. 2024 Jul;
125(3):278-285.
PMID: 39009007
Background: While direct oral anticoagulants (DOACs) may be viewed as simpler to manage then warfarin, they present their own unique management challenges resulting in frequent off-label dosing. It is unknown...
4.
Schaefer J, Errickson J, Kong X, Ali M, DeCamillo D, Edupuganti S, et al.
Res Pract Thromb Haemost
. 2024 Jul;
8(4):102449.
PMID: 38983902
Background: For patients anticoagulated with direct oral anticoagulants (DOACs) or warfarin and on aspirin (ASA) for nonvalvular atrial fibrillation and/or venous thromboembolism, it is unclear if bleeding outcomes differ. Objectives:...
5.
Kurlander J, Helminski D, Yuan L, Krein S, Lanham M, Henstock J, et al.
Res Pract Thromb Haemost
. 2024 Jun;
8(4):102421.
PMID: 38827255
Background: Overuse of antiplatelet therapy and underuse of gastroprotection contribute to preventable bleeding in patients taking anticoagulants. Objectives: (1) Determine the feasibility of a factorial trial testing patient activation and...
6.
Haymart B, Kong X, Ali M, Schaefer J, Froehlich J, Ryan N, et al.
Am J Med
. 2024 Jan;
137(5):449-453.
PMID: 38280559
Background: For patients on warfarin for mechanical heart valve replacement, the 2020 American College of Cardiology and American Heart Association Guidelines recommend only adding aspirin in patients with a specific...
7.
Feldeisen D, Alexandris-Souphis C, Haymart B, Gu X, Perry L, Watts S, et al.
J Thromb Thrombolysis
. 2022 Nov;
55(1):141-148.
PMID: 36326967
A lack in patient knowledge of warfarin therapy is associated with poor adherence. This knowledge gap may result in a lower INR Time in Therapeutic Range (TTR). To investigate association...
8.
Joyce E, Haymart B, Kong X, Ali M, Carrigan M, Kaatz S, et al.
J Am Heart Assoc
. 2022 Oct;
11(21):e025471.
PMID: 36285782
Background For more than a decade, guidelines have recommended a limited 3 months of anticoagulation for the treatment of provoked venous thromboembolism (VTE). How closely real-world practice follows guideline recommendations...
9.
Schaefer J, Errickson J, Gu X, Alexandris-Souphis T, Ali M, Haymart B, et al.
JAMA Netw Open
. 2022 Sep;
5(9):e2231973.
PMID: 36121653
Importance: For some patients receiving warfarin, adding aspirin (acetylsalicylic acid) increases bleeding risk with unclear treatment benefit. Reducing excess aspirin use could be associated with improved clinical outcomes. Objective: To...
10.
Song M, Haymart B, Kong X, Ali M, Kaatz S, Kozlowski J, et al.
Vasc Med
. 2022 Apr;
27(4):382-384.
PMID: 35400235
No abstract available.